Omeros (OMER) Q2 2024 earnings summary

Executive summary

• Net loss for Q2 2024 was $56 million ($0.97/share), up from $37.2 million ($0.63/share) in Q1 2024 and $37.3 million ($0.59/share) in Q2 2023, driven by significant one-time expenses.

• Major non-recurring costs included $17.6 million for narsoplimab manufacturing, $21.2 million for discounted debt repurchase, and $1.9 million in transaction costs.

• Completed a major debt restructuring, repurchasing $118.1 million of 2026 notes at a 25% discount, funded by a $67.1 million term loan and $21.2 million cash, reducing outstanding notes by over half to $98 million and extending maturity to June 2028.

• Cash and investments at June 30, 2024, totaled $158.9 million.

• Monetized future OMIDRIA royalties, receiving $115.5 million in February 2024, and retains rights to ex-US royalties and potential milestone payments.

Financial highlights

• Q2 2024 net loss: $56 million, compared to $37.2 million in Q1 2024 and $37.3 million in Q2 2023; six-month net loss was $93.2 million, up from $71 million year-over-year.

• Research and development expenses rose to $45.3 million in Q2 2024 from $29.6 million in Q2 2023, mainly due to increased narsoplimab manufacturing and zaltenibart clinical costs.

• Selling, general and administrative expenses increased to $13.8 million in Q2 2024 from $11.3 million in Q2 2023, driven by legal and financial advisory costs.

• OMIDRIA royalties in Q2: $10.9 million on $36.4 million net sales, up from $10.7 million on $35.7 million in Q2 2023.

• Interest expense in Q2: $9.2 million, up from $7.9 million in Q2 2023, reflecting higher borrowings.

Outlook and guidance

• Q3 operating costs expected to decrease by ~$20 million due to absence of Q2's one-time expenses and lower narsoplimab manufacturing costs.

• Q3 interest income projected at $2.5 million; interest expense at $8.2 million.

• Income from discontinued operations in Q3 expected to be $7–8 million.

• Phase III trials for zaltenibart in PNH to initiate later in 2024; C3G phase III to start in Q1 2025.

• Additional FDA meeting scheduled regarding narsoplimab BLA resubmission; update on timing expected when more information is available.